Summary by Futu AI
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 Registration Statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment pertains to a proposed public offering of securities, including up to 3,322,259 shares of common stock, Pre-Funded Warrants to purchase an equivalent number of shares, and Series B-1 and B-2 Common Warrants to purchase up to 3,322,259 shares of common stock each. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities or proceeds required for closing. The securities may be sold to purchasers whose ownership would exceed 4.99% of outstanding common stock, in the form of Pre-Funded Warrants...Show More